Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $11.86 Average Target Price from Brokerages
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been given an average rating of “Hold” by the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. […]
Previous post
Chicago White Sox trade reliever Aaron Bummer to the Atlanta Braves in a 6-player deal
More Stories
Dr. Oz Says Anti-Fraud Effort Coming to ‘All 50 States’
By Jack Phillips Dr. Mehmet Oz, the administrator of the agency overseeing Medicaid and Medicare, announced Tuesday that his agency’s...
US Retail Sales Jump in March as Higher Gas Prices Lift Spending
By Bill Pan Americans kept on spending in March amid a sharp rise in gasoline prices, new government data suggest....
Trump Announces Extension of Iran Ceasefire
By Jack Phillips President Donald Trump on Tuesday announced he is extending a ceasefire with Iran, citing what he said...
Democratic Rep. Cherfilus-McCormick Resigns Ahead of Ethics Committee Sanctions Hearing
By Chase Smith Rep. Sheila Cherfilus-McCormick (D-Fla.) resigned from Congress on Tuesday, stepping down hours before the House Ethics Committee...
Is Hell’s Paradise Season 3 Renewed? Release Date, Plot, and Episodes
With the recent release of the anime series Hell’s Paradise, fans are curious to know about the renewal status of...
Who is Lana Condor? Movies and Controversy at the Fashion Trust Awards Show
From an orphanage to becoming a well-known face in the American film industry, Lana has come a long way. Want...
